뒤로
Pelthos Therapeutics Inc (PTHS) 수입
PTHS 주가 차트
PTHS 수입
Pelthos Therapeutics Inc
$22
0%
$0
종가: Mar 24, 16:00:00 GMT-4
$22
0%
$0
애프터마켓: Mar 24, 20:00:00 GMT-4
최신 수익 결과: Q4 '25
보고됨: 2026-03-19
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
PTHS의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Pelthos Therapeutics Inc PTHS의 지난 분기 매출 실적은 어땠나요?
Pelthos Therapeutics Inc의 매출 추정치는 얼마인가요?
Pelthos Therapeutics Inc의 수익 품질 점수는 얼마인가요?
Pelthos Therapeutics Inc는 언제 수익을 보고하나요?
Pelthos Therapeutics Inc의 예상 수익은 얼마인가요?
Pelthos Therapeutics Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$22
시가
$22
일일 범위
$22 - $22.5
52주 범위
$9 - $54.29
거래량
2.5K
평균 거래량
10.5K
배당수익률
--
EPS(TTM)
-12.80
시가총액
$71.2M
PTHS란 무엇인가요?
Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. The company is headquartered in Durham, North Carolina and currently employs 4 full-time employees. The company went IPO on 2024-02-16. The firm's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The firm also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.